Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APP to launch Imipenem and Clilastatin, Meropenen in US
The company will begin the shipment of Meropenem for Injection in 500mg and 1gm single dose vials from 13 February 2012. The Imipenem and Cilastatin for Injection in
The company will begin the shipment of Meropenem for Injection in 500mg and 1gm single dose vials from 13 February 2012. The Imipenem and Cilastatin for Injection in
The offering includes a new set of cloud-based BI applications that aligns sales and marketing spend with market-driven revenue outcomes linked to comprehensive internal and external market data
The payment represents the final phase of the Plavix patent litigation between the companies and Apotex, which was initiated in 21March 2002. Apotex also paid $1,258,682 in interest
This SDD technology will improve the bioavailability of compounds with low aqueous solubility. Bend Research will continue to provide formulation, development, analytical, engineering and manufacturing services to Lilly
LipiGesic M is a homeopathic product comprising feverfew and ginger, formulated for acute migraine headache relief. Feverfew (Pyrethrum Parthenium), the active ingredient in LipiGesic M, is an herb
Intellect’s new approach specifically targets neoepitopes that are formed following cleavage of intact tau protein by executioner caspases. The pathological process is stimulated by an accumulation of amyloid
Pertuzumab, a HER2 dimerization inhibitor is designed specifically to prevent the HER2 receptor from with other HER receptors, thereby inhibiting the growth and formation of tumor. The proposed
The CryoStem has acquired adipose tissue samples utilizing a mini-liposuction procedure. A total of sixty milliliters (approximately 2 fluid ounces) of adipose tissue was collected in the physician’s
OncoCEE-BR detects CTCs, which are rare, and determines the patient’s HER2 status by fluorescence in situ hybridization (FISH). The companies will market and sell the OncoCEE-BR CTC test
The MDA grant will be used to evaluate the effect of the pharmacological chaperone AT2220 on immunogenicity related to the ERT alglucosidase alfa, the approved treatment for Pompe